MPEP § 2413.01(b) — The “Sequence Listing XML” Must Be Valid According To the DTD

Ninth Edition, Revision 01.2024 · last revised R-01.2024

[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]

37 CFR 1.833 Requirements for a “Sequence Listing XML” for nucleotide and/or amino acid sequences as part of a patent application filed on or after July 1, 2022.

  • *****

  • (b) The “Sequence Listing XML” presented in accordance with paragraph (a) of this section must further:
    • (1) Be valid according to the Document Type Definition (DTD) as presented in WIPO Standard ST.26, Annex II.

  • *****

37 CFR 1.833(b)(1) incorporates the DTD requirement of WIPO Standard ST.26 such that a “Sequence Listing XML” must conform to the Document Type Definition (the document that sets out the structure and use of elements and attributes in an XML compliant document) presented in Annex II of WIPO Standard ST.26. Use of the WIPO Sequence tool will enable a user to generate a “Sequence Listing XML” that conforms to the DTD in Annex II of WIPO Standard ST.26. See MPEP § 2418.

Cited authority